Saving lives through innovative molecular diagnostic solutions. Mainz Biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. We develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. Visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science. molecular genetic in-vitro diagnostics

18 similar entities Type: Startup Activities: deeptech biotech

Revolutionising Cancer Detection Through Liquid Biopsy The Vortex VTX-1 CTC isolation platform combines high-performance engineering with clinical simplicity. Compact, automated, and easy to integrate, our solution delivers high-purity CTCs ready for downstream analysis—without the need for complex protocols or extensive training. Precision medicine starts here Circulating Tumor Cells, Cancer biomarkers, Microfluidic, Cancer research, Cancer diagnosis, Liquid biopsy, and Cancer monitoring

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ultra-sensitive and multiplex nucleic acid assays for fast and cost efficient mutation detection in liquid biopsy Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala …

9 similar entities Type: Startup Activities: biotech deeptech

Innovating for cancer patients METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions. ctDNA, Cancer, Biomarqueurs, circulating tumoral DNA, Liquid biopsy, Precision medicine, and ddPCR

14 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Leader in the development, production and sales of pharmacogenetics tests for cancer precision medicine. Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions …

28 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

FAST LABORATORY DIAGNOSTICS OaCP, Oncology and Cytogenetic Products, deals with the creation of chemical and biotechnological products for fast diagnostics. We believe that the quality of work in molecular biology and molecular cytogenetics is fundamental, that it can also be economical (Smart-ISH Solve) and - why not - rapid (Rapid-ISH Integra). Thanks to the multi-year research conducted with the University of Bologna, we have developed the DoMo Genetics line of reagents but we don't stop! Our mission is to provide faster, more budget-conscious and easier-to-use tools to the molecular biology laboratory professional, to improve the quality of life of cancer …

Type: Startup Activities: deeptech biotech

Early cancer detection in blood AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. Biotechnology, Cancer Diagnostics, Innovation, Personalized medicine, Blood test, and Biomarkers

74 similar entities Type: Startup Activities: biotech deeptech

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

41 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genomics Imaging for Precision Medicine Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for …

8 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology